Pages that link to "Q33929529"
Jump to navigation
Jump to search
The following pages link to The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma (Q33929529):
Displaying 50 items.
- Radiotherapy combination opportunities leveraging immunity for the next oncology practice (Q26738443) (← links)
- Targeting the indoleamine 2,3-dioxygenase pathway in cancer (Q26775471) (← links)
- The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity (Q26785900) (← links)
- Strategies for combining immunotherapy with radiation for anticancer therapy (Q26796675) (← links)
- Biomarkers for glioma immunotherapy: the next generation (Q26825496) (← links)
- The role of IDO in brain tumor immunotherapy (Q26830399) (← links)
- Trial watch: IDO inhibitors in cancer therapy (Q27006866) (← links)
- Targeting immune checkpoints in malignant glioma (Q28072012) (← links)
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance (Q34512092) (← links)
- A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy (Q36635458) (← links)
- Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy (Q37079141) (← links)
- Effect of Necrosis on the miRNA-mRNA Regulatory Network in CRT-MG Human Astroglioma Cells (Q38433156) (← links)
- Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. (Q38438763) (← links)
- Major developments in the design of inhibitors along the kynurenine pathway (Q38808400) (← links)
- Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015). (Q38832886) (← links)
- Developing immunotherapeutic strategies to target brain tumors (Q38851464) (← links)
- Modulation of cancer-specific immune responses by amino acid degrading enzymes (Q39045520) (← links)
- Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases. (Q39185463) (← links)
- IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment (Q39294822) (← links)
- The interplay between metabolic remodeling and immune regulation in glioblastoma (Q39328710) (← links)
- Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer (Q39578716) (← links)
- Aberrant Kynurenine Signaling Modulates DNA Replication Stress Factors and Promotes Genomic Instability in Gliomas (Q41720039) (← links)
- Indoleamine-2,3-dioxygenase and Interleukin-6 associated with tumor response to neoadjuvant chemotherapy in breast cancer (Q47157830) (← links)
- IDO1 in cancer: a Gemini of immune checkpoints. (Q47836812) (← links)
- Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA. (Q48177244) (← links)
- Discovery of IDO1 and DNA dual targeting antitumor agents. (Q48589619) (← links)
- Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model (Q48766890) (← links)
- Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment (Q49592881) (← links)
- IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients (Q50103704) (← links)
- Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors. (Q52579088) (← links)
- The expression and prognostic relevance of indoleamine 2,3-dioxygenase in tongue squamous cell carcinoma. (Q53146697) (← links)
- Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. (Q55346219) (← links)
- Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in Glioblastoma. (Q55457248) (← links)
- Molecular signature of response to preoperative radiotherapy in locally advanced breast cancer (Q57062238) (← links)
- Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond (Q57159199) (← links)
- Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer (Q58750429) (← links)
- Indoleamine 2,3-dioxygenase 1 and Programmed Cell Death-ligand 1 Co-expression Predicts Poor Pathologic Response and Recurrence in Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy (Q64244075) (← links)
- Inhibition Mechanism of Indoleamine 2, 3-Dioxygenase 1 (IDO1) by Amidoxime Derivatives and Its Revelation in Drug Design: Comparative Molecular Dynamics Simulations (Q89668283) (← links)
- Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer (Q90007129) (← links)
- Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway (Q90055911) (← links)
- Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas (Q90218743) (← links)
- Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy (Q90254034) (← links)
- Limited Effect of Indolamine 2,3-Dioxygenase Expression and Enzymatic Activity on Lupus-Like Disease in B6.Nba2 Mice (Q90290659) (← links)
- Immune control by amino acid catabolism during tumorigenesis and therapy (Q91272360) (← links)
- Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond (Q91559758) (← links)
- Cold Atmospheric Plasma as an Adjunct to Immunotherapy for Glioblastoma Multiforme (Q91711701) (← links)
- PEG-Derivatized Dual-Functional Nanomicelles for Improved Cancer Therapy (Q92403213) (← links)
- Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma (Q92457071) (← links)
- Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase (Q93371164) (← links)
- Nanomedicine-based immunotherapy for central nervous system disorders (Q95936527) (← links)